John Arbuthnot, CEO of Delta 9 Bio-Tech #DN discusses the company's recent quarter and their success and consistent growth with their numbers. John credits his team that has implemented changes and brought the company to this level and how they compare to other companies in this sector.
Interesting key talking points below!
(2:55) Diversified Strategy Reduced Impact of Covid
(4:50) Financial Highlights
(6:50) Why Doesn't Share Price Correlate With Financials?
(9:30) Why Did Canaccord Raise DN Price Target?
(12:17) DN's Enterprise Value is a Shining Star
We hope you ENJOY and Don’t Forget...
📈Built by Investors, for Investors📈
Tweets by FTMInvest